RESUMO
To establish the spectrum of toxicities and supportive care required during intensive post remission chemotherapy with high dose Ara-c in Acute Myeloid Leukaemia. A retrospective study. From Aug. 95 to Feb. 98. Department of Radiotherapy and Oncology CMH Rawalpindi and Armed Forces Institute of Pathology, Rawalpindi. Eleven patients of acute myeloid leukaemia achieving complete remission, received total of 36 courses of HidAC. Toxicities occurring and supportive care required during intensive post remission chemotherapy with HidAC. Most common toxicities included fever, bleeding and conjunctivitis. Two patients died due to cerebral bleeding and DIC. Patients were managed with antibiotics, platelet concentrates and topical steroids. No patient developed CNS toxicity